Madrigal Pharmaceuticals trended early Monday as retail traders hyped buyout speculation, driven by strong two-year clinical data for its NASH drug Rezdiffra and fresh analyst target hikes. Interest in liver and metabolic disease drugs has surged industry-wide, adding fuel to expectations of a huge deal as Madrigal momentum accelerates.